期刊
NEUROLOGY
卷 92, 期 19, 页码 E2273-E2285出版社
LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1212/WNL.0000000000007456
关键词
-
资金
- University Hospital Federation OncoAge (FHU OncoAge) consortium (Nice)
- Centre Hospitalier Universitaire de Nice [13AOI-01]
- French Government (National Research Agency, ANR) through the Investments for the Future (LABEX SIGNALIFE) [ANR-13-BSV1-0004-04, ANR-11-LABX-0028-01]
- Prinses Beatrix Spierfonds [W. OP14-01, W. OB17-01]
- National Institute of Neurologic Disorders and Stroke [P01 NS069539]
- Stichting Spieren voor Spieren
- National Institute of Arthritis Musculoskeletal and Skin Disease [R01AR066248]
- FHU OncoAge
- NATIONAL INSTITUTE OF ARTHRITIS AND MUSCULOSKELETAL AND SKIN DISEASES [R01AR066248] Funding Source: NIH RePORTER
- NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE [P01NS069539] Funding Source: NIH RePORTER
Objective To compare the clinical features of patients showing a classical phenotype of facioscapulo-humeral muscular dystrophy (FSHD) with genetic and epigenetic characteristics of the FSHD1 and FSHD2 loci D4Z4 and SMCHD1. Methods This is a national multicenter cohort study. We measured motor strength, motor function, and disease severity by manual muscle testing sumscore, Brooke and Vignos scores, clinical severity score (CSS), and age-corrected CSS, respectively. We correlated these scores with genetic (D4Z4 repeat size and haplotype; SMCHD1 variant status) and epigenetic (D4Z4 methylation) parameters. Results We included 103 patients: 54 men and 49 women. Among them, we identified 64 patients with FSHD1 and 20 patients with FSHD2. Seven patients had genetic and epigenetic characteristics of FSHD1 and FSHD2, all carrying repeats of 9-10 D4Z4 repeat units (RU) and a pathogenic SMCHD1 variant. In the remaining patients, FSHD was genetically excluded or remained unconfirmed. All clinically affected SMCHD1 mutation carriers had a D4Z4 repeat of 9-16 RU on a disease permissive 4qA haplotype. These patients are significantly more severely affected by all clinical scales when compared to patients with FSHD1 with upper-sized FSHD1 alleles (8-10 RU). Conclusion The overlap between FSHD1 and FSHD2 patients in the 9-10 D4Z4 RU range suggests that FSHD1 and FSHD2 form a disease continuum. The previously established repeat size threshold for FSHD1 (1-10 RU) and FSHD2 (11-20 RU) needs to be reconsidered.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据